Abbvie Inc ABBV

$261.59 -1.70 (-0.65%)

Valuation

Market cap
470,461,632,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
24.32
Forward PE
18.81
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
4,328,188
Avg volume
4,652,506
Day's range
$261.59 – $265.36
Shares out
1,766,793,000
Stochastic %K
28%
Beta
0.29
Analysts
Strong Sell
Price target
$277.87

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

SellasgpsCurativeBAT11 Sep 30, 5:33 PM
$ABBV $BMY $JNJ $PFE $SLS Pfizer CEO Dr. Bourla friend of Sellas CEO Dr. Stergiou. Dr. Bourla Cancer is not one disease. It hides, it adapts, it comes back different. That is why the research is so complicated, and why it has remained the greatest challenge in medicine. But the science is breaking, and we can now see opportunities to defeat it that we could not even dream of a few years ago. Going after a problem that big takes focus, and the same is true for all of us, whatever your goal may be. Focus enables ambition. When it is guided by real purpose, you can go further than you ever thought possible. That is why we dedicate the greatest share of our research to cancer, and why I am more optimistic than ever about what that will mean for patients. On #WorldCancerResearchDay, my thanks to every researcher working to get us there. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Sep 30, 4:36 PM
$ABBV $BMY $JNJ $PFE $SLS 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth. ✌️🙏❤️‍🩹
1 replies
Quantumup Sep 30, 12:46 PM
Citizens reiterated $IMMX Market Outperform-$23 on what it believes could be best-in-class results in relapsed/refractory AL amyloidosis and continues to be buyers. $REGN $ABBV JNJ SNY AZN Citizens said in its note to investors: Yesterday, Immix reported interim results based on all 45 patients treated in the NEXICART-2 trial, showcasing what we believe could be best-in-class results in relapsed/refractory AL amyloidosis. The company concurrently raised $125MM in an underwritten offering from dedicated marquee healthcare investors. Based on the conference call and the capital raised, we remain confident in the BLA submission for NXC-201 in 1H27. With a potential commercial launch in 2028, the initiation of a front-line study slated for 2027, and a solid cash position of $357.1MM (proforma), we believe Immix represents an attractive investment opportunity and continue to be buyers amidst the current weakness in shares.
0 replies
OpenOutcrier Sep 30, 12:42 PM
$ABBV (+0.4% pre) AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1 https://ooc.bz/l/116003
0 replies
biolover Sep 30, 11:49 AM
$ABBV $VKTX $ABBV headline data today on GUBRA amylin presentation. Someone probably will provide slides. But no details on all AEs and 4.4% placebo adjusted DC due to GI AE is not good for an amylin. It’s higher than what reported with leading incretins $LLY TZP and $VKTX 2735 Half life 10-12 days is C/W with what available out there from other mechanisms as CEO continues to mull combination ( which doesn’t seem to be a good idea with this amylin based on above )
2 replies
biolover Sep 30, 11:38 AM
$VKTX Shorts got to watch t1/2 is in the range of VK2735. That’s what $ABBV looking for. Partnerships take time ABBV-295 demonstrated dose-proportional increases in plasma exposure across cohorts. Median Tmax ranged from 24.0 to 48.1 hours, and the mean half-life ranged from 10.7 to 12.3 days, a profile that supported the once-weekly, every-other-week, and monthly regimens evaluated in the study.1
0 replies
TalkMarkets Sep 30, 6:13 AM
Defensive Dividends: 3 Companies Investors Can Rely On $JNJ $KO $ABBV Also Mentions: $ABT https://talkmarkets.com/article/defensive-dividends-3-companies-investors-can-rely-on
0 replies
Quantumup Sep 29, 6:04 PM
BofA⬆️ $IMMX's PT to $30,⬆️LoS for NXC-201 in r/r AL amyloidosis to 60% (prev. 50%) and said -- Positive interim data validates opportunity in r/r AL amyloidosis; Reiterate Buy—NXC-201 showed deep & durable CR in r/r AL amyloidosis $REGN $ABBV JNJ SNY AZN Here's what else BofA had to say in its note to investors: https://x.com/Quantumup1/status/2104995552740147393?s=20
0 replies